Defactinib hydrochloride is under clinical development by Verastem and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Defactinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Defactinib hydrochloride overview
Defactinib hydrochloride (VS-6063) is under development for the treatment of gastroesophageal junction carcinoma, metastatic uveal melanoma, KRAS-mutated NSCLC, colorectal cancer, brain metastases from cutaneous melanoma, pancreatic ductal adenocarcinoma, metastatic adenocarcinoma of the pancreas, endometrial cancer, prostate cancer, epithelial ovarian cancer, fallopian tube cancer, low-grade serous ovarian cancer, peritoneal cancer, recurrent glioblastoma multiforme and glioblastoma multiforme. The drug candidate is administered by oral route. VS-6063 is a selective inhibitor of the focal adhesion kinase (FAK1) or protein tyrosine kinase 2 (PTK-2).
The drug candidate was also under development for the treatment of pancreatic cancer, malignant pleural mesothelioma, triple negative breast cancer and solid tumors (non-hematologic malignancy).
Verastem overview
Verastem is a late-stage development biopharmaceutical company that develops and commercializes new medicines to treat cancer. The company’s pipeline products include avutometinib and defactinib combinations that treat low-grade serous ovarian cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer and melanoma, among others. Its avutometinib is an orally available small molecule rapidly accelerated fibrosarcoma/mitogen-activated protein kinase (RAF/MEK) clamp that inhibits the renal artery stenosis (RAS) sarcoma (RAS)/RAF/MEK, ERK mitogen-activated pathway kinase pathway which is involved in cell proliferation, migration, transformation and survival of tumor cells. Verastem’s defactinib is a selective focal adhesion kinase-1 (FAK) inhibitor monotherapy that targets solid tumors. The company operates through its subsidiaries in the US and Germany. Verastem is headquartered in Needham, Massachusetts, the US.
For a complete picture of Defactinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
